Professor | Di Zhu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Di Zhu
Contact Information	zhudi@fudan.edu.cn
Language ability	Chinese, English
Province	Shanghai

Upload Avatar (500 x 500)

Name

Di Zhu

Contact Information

zhudi@fudan.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	Fudan University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2001.09—2005.07 Bachelor's in Biochemistry and Molecular Biology: Shandong University 2005.09—2010.07 Ph.D. in Biochemistry and Molecular Biology: Graduate School of the Chinese Academy of Sciences
Work Experience	2011.01—2015.06 - Dana-Farber Cancer Institute, Harvard University - Postdoctoral Researcher 2015.07—2016.05 - Dana-Farber Cancer Institute, Harvard University - Lecturer (Junior Faculty) 2016.10—2021.07 - School of Pharmacy, Fudan University - Doctoral Supervisor 2017.01—Present - Minhang Hospital, Fudan University - Part-time Professor 2021.08—Present - Basic Medical Sciences, Fudan University - Doctoral Supervisor
Awards	2024: Fudan University Excellent Doctoral Dissertation Supervisor 2024: Bronze Award at the 35th Shanghai Excellent Invention Selection Competition 2023: Second Prize of the Chinese Anti-Cancer Association Science and Technology Award 2022: Shanghai Bioengineering Society 'Dongfulong' Bioengineering Excellent Young Scientist Award 2019: Zeng Ai·Changmu Academic Award, Zeng Ai China Foundation 2010: FEBS Youth Travel Fellowship, Federation of European Biochemical Societies

University/Lab Affiliation and Title

Fudan University

Faculty

Basic Medical Sciences

Academic Background & Achievements

2001.09—2005.07 Bachelor's in Biochemistry and Molecular Biology: Shandong University
2005.09—2010.07 Ph.D. in Biochemistry and Molecular Biology: Graduate School of the Chinese Academy of Sciences

Work Experience

2011.01—2015.06 - Dana-Farber Cancer Institute, Harvard University - Postdoctoral Researcher
2015.07—2016.05 - Dana-Farber Cancer Institute, Harvard University - Lecturer (Junior Faculty)
2016.10—2021.07 - School of Pharmacy, Fudan University - Doctoral Supervisor
2017.01—Present - Minhang Hospital, Fudan University - Part-time Professor
2021.08—Present - Basic Medical Sciences, Fudan University - Doctoral Supervisor

Awards

2024: Fudan University Excellent Doctoral Dissertation Supervisor
2024: Bronze Award at the 35th Shanghai Excellent Invention Selection Competition
2023: Second Prize of the Chinese Anti-Cancer Association Science and Technology Award
2022: Shanghai Bioengineering Society 'Dongfulong' Bioengineering Excellent Young Scientist Award
2019: Zeng Ai·Changmu Academic Award, Zeng Ai China Foundation
2010: FEBS Youth Travel Fellowship, Federation of European Biochemical Societies

Areas of Focus	Pharmacological Mechanisms Targeting BCL9/β-catenin Development of New Drugs for Tumor Immunotherapy
Publications	Interferon-α potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment., Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., Zhu, Y., Huang, C., Yang, X., Shi, Y., Qiu, S., Sun, H., Zhu, A., Zhou, J., Xu, Y., Zhu, D., Fan, J., 2022 RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers., Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., Xie, D., Zhu, D., 2022 BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer., Feng, M., Wu, Z., Zhou, Y., Wei, Z., Tian, E., Mei, S., Zhu, Y., Liu, C., He, F., Li, H., Xie, C., Jin, J., Dong, J., Yang, D., Yu, K., Qian, J., Lambrechts, D., Wang, M., Zhu, D., 2021 BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer., Wang, X., Feng, M., Xiao, T., Guo, B., Liu, D., Liu, C., Pei, J., Liu, Q., Xiao, Y., Rosin-Arbesfeld, R., Shi, Y., Zhou, Y., Yang, M., Feng, Y., Jiang, Y., Shao, Z., Yu, K., Zhu, D., 2021 Discovery of a novel, potent, and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumor efficacy., Liu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y., Zhu, D., 2021 RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer., Tian, E., Yu, M., Feng, M., Wang, Y., Xie, Q., Zhu, D., 2021 T-cell-based immunotherapy in colorectal cancer., Feng, M., Zhao, Z., Yang, M., Ji, J., Zhu, D., 2021 Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells., Feng, M., Jin, J., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Raf, S., Zhu, A., Feng, Y., Zhu, D., 2019 The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells., Zhu, D., Wang, Z., Zhao, J., Calimeri, T., Meng, J., Hideshima, T., Fulciniti, M., Kang, Y., Ficarro, S., Tai, Y., Hunter, Z., McMilin, D., Tong, H., Mitsiades, C., Wu, C., Treon, S., Dorfman, D., Pinkus, G., Munshi, N., Tassone, P., Marto, J., Anderson, K., Carrasco, R., 2015 Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling., Takada, K.#, Zhu, D.#, Bird, GH. #, Sukhdeol, K., Zhao, J., Mani, M., Lemieux, M., Carrasco, D., Ryan, J., Horst, D., Fulciniti, M., Mushi, NC., Xu, W., Kung, AL., Shivdasani, R., Walensky, L., Carrasco, R., 2012

Areas of Focus

Pharmacological Mechanisms Targeting BCL9/β-catenin
Development of New Drugs for Tumor Immunotherapy

Publications

Interferon-α potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment., Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., Zhu, Y., Huang, C., Yang, X., Shi, Y., Qiu, S., Sun, H., Zhu, A., Zhou, J., Xu, Y., Zhu, D.*, Fan, J.*, 2022
RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers., Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., Xie, D., Zhu, D.*, 2022
BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer., Feng, M., Wu, Z., Zhou, Y., Wei, Z., Tian, E., Mei, S., Zhu, Y., Liu, C., He, F., Li, H., Xie, C., Jin, J., Dong, J., Yang, D., Yu, K., Qian, J., Lambrechts, D.*, Wang, M.*, Zhu, D.*, 2021
BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer., Wang, X., Feng, M., Xiao, T., Guo, B., Liu, D., Liu, C., Pei, J., Liu, Q., Xiao, Y., Rosin-Arbesfeld, R., Shi, Y., Zhou, Y., Yang, M., Feng, Y., Jiang, Y., Shao, Z., Yu, K.*, Zhu, D.*, 2021
Discovery of a novel, potent, and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumor efficacy., Liu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y.*, Zhu, D.*, 2021
RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer., Tian, E., Yu, M., Feng, M., Wang, Y., Xie, Q.*, Zhu, D.*, 2021
T-cell-based immunotherapy in colorectal cancer., Feng, M., Zhao, Z., Yang, M., Ji, J., Zhu, D.*, 2021
Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells., Feng, M., Jin, J., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Raf, S., Zhu, A., Feng, Y.*, Zhu, D.*, 2019
The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells., Zhu, D., Wang, Z., Zhao, J., Calimeri, T., Meng, J., Hideshima, T., Fulciniti, M., Kang, Y., Ficarro, S., Tai, Y., Hunter, Z., McMilin, D., Tong, H., Mitsiades, C., Wu, C., Treon, S., Dorfman, D., Pinkus, G., Munshi, N., Tassone, P., Marto, J., Anderson, K., Carrasco, R.*, 2015
Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling., Takada, K.#, Zhu, D.#, Bird, GH. #, Sukhdeol, K., Zhao, J., Mani, M., Lemieux, M., Carrasco, D., Ryan, J., Horst, D., Fulciniti, M., Mushi, NC., Xu, W., Kung, AL., Shivdasani, R., Walensky, L.*, Carrasco, R.*, 2012

Bcl9 Β-Catenin Pharmacology Mechanisms Tumor Immunotherapy Drug Development Cancer Targeting Research

Xian Wang - Peking University

Yang Li - Peking University

Xiaowei Zhang - Peking University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us